Natera

Natera

Signatera is a personalized, tumor-informed assay, optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Results are based on the unique signature of a patient’s tumor by tracking mutations at the source and enabling accurate monitoring of disease over time. Discover more at: natera.com/oncology

Yes

Breast Cancer, Gastrointestinal (Colorectal) Cancer, Genitourinary Cancer, Human Genetics, Immunotherapy